Our Impact


|Case Study

Disease Impact Overview


On the face of it, Marcella and Beatriz have little in common. Born into a family with means, and educated at some of the best schools in Europe, Marcella is now a corporate executive living in Barcelona, Spain. An ocean away, Beatriz’s family belongs to the Guarani ethnic group in rural Bolivia. Just a teenager when trafficked from her rural home and forced to become a domestic worker, Beatriz lives in slums on the outskirts of Cochabamba – an area with few signs of economic progress: water is still collected and carried by hand, there is no electricity, and the homes are simple mud hut structures.

Unknown to Marcella and Beatriz, who are each anticipating the birth of their first child, both carry the T.cruzi parasite responsible for Chagas disease, which puts the health of their unborn children at risk. Named after Brazilian physician Carlos Chagas who first described the disease, it is spread by the bite of insects known as triatominae, or “kissing bugs,” that are endemic to Latin American countries. In a historical study of 66 infants where the parasite was passed from the mother, less than half of the infants lived beyond 2 years of age1.

MaBeatriz was infected when a kissing bug carrying the parasite bit her lip. Like the majority of those infected, Beatriz did not show any immediate symptoms of the disease; she may eventually develop cardiac disorders, enlargement of the esophagus or colon, or neurological disorders 10 to 20 years after the initial infection2. Since the disease will likely go undiagnosed, it is likely that she will pass it to her unborn child and possibly to others through blood donations.
_image_ Photo Credit: DNDi
  • Kissing bugs live in the cracks of the mud walls of poor-quality housing and on the fur of livestock. In the impoverished areas of Bolivia, estimates indicate that nearly 50% of residences have triatomine infestation, with over 30% of those bugs carrying the T. cruzi parasite3. Chagas disease affects an estimated 1.8 million people in Bolivia (roughly 15% of the population)4 and between 6 to 7 million people worldwide5 – with 50,000 new cases occurring per year.6 Approximately 12,000 people die from Chagas disease each year and 65 million people in the Americas alone are at risk for contracting the disease.7

    Marcella, living thousands of miles from the endemic regions where kissing bugs are present, was infected with Chagas disease when she received a blood transfusion containing the parasites. She too risks passing the disease to her child and spreading the disease further.

  • “MEASURES TO LIMIT CHAGAS SPREAD BY BLOOD TRANSFUSION”

    An increase in blood donor screening in endemic countries has helped limit risk of Chagas disease transmission by blood transfusion. Similar screening is being instituted in non-endemic countries such as the US, France, and Spain, which receive large numbers of immigrants from high-risk areas of Latin America. The risk of transmission in non-endemic countries is very real. A recent report found that more than 15% of Bolivian patients receiving treatment at a primary care center in Barcelona, Spain tested positive for the Chagas parasite.
    (Roca, C et al. PLoS neglected tropical diseases 5.4 (2011): e1135
Chagas disease is emerging as an important public health challenge globally. The same is true for visceral leishmaniasis (VL). Much like Chagas disease, VL is a neglected disease spread by the bite of an insect (the phlebotomine sandfly). Female sandflies in need of blood for egg development are infected with Leishmania parasites when they suck blood from an infected person and then pass the parasite to uninfected humans as they feed. VL causes irregular bouts of fever, weight loss, enlargement of the spleen and liver, and anemia. If left untreated, VL is fatal within 2 years of infection8.

VL is especially prevalent in impoverished areas with high population density; inadequate sanitation creates more sandfly breeding sites and poor construction allows them to easily enter homes. There are an estimated 300,000 new VL cases every year, with the majority occurring in six countries: Bangladesh, Brazil, Ethiopia, India, South Sudan and Sudan. Each year, 20,000 people die from VL and an estimated 310 million people are at risk for contracting the disease9.

Both diseases inflict devastating tolls on the economies of regions they affect. The global cost of Chagas disease, for example is estimated at $7 billion annually10. The majority of this cost burden stems from losses in workforce productivity. Globalization and immigration patterns between Latin America and the rest of the world are also compounding the spread and economic impacts of the disease. In the case of VL, a recent analysis for one of the worst affected regions in India showed that 7 months of an individual’s income was spent on treatments for the disease. In this community, 87% of households were forced to take out loans to cope with the disease burden, further illustrating how this disease contributes to increasing poverty and social decline11.

Current Treatment Options


The similarities between Chagas disease and VL do not end with their mode of transmission; both diseases are challenging to treat since the few options that exist are expensive, inefficient, and cause serious side effects. Existing VL therapies often have toxic side effects and limited benefits.
Amphotericin B liposome, considered the best existing therapy, is effective but extremely expensive ($126 to $252 for each treatment). Additionally, the product is not stable at the high temperatures in regions affected by the disease, and is given by painful injection ⎯ both of which limit patient access to and adherence with therapy.
_image_ Photo Credit: DNDi There are even fewer treatment options for Chagas disease. Nifurtimox and Benznidazole are the only recognized treatments. Both drugs are effective when given soon after infection, but the efficacy of these drugs decreases significantly as the disease progresses from the acute to the chronic phase5. However, because the majority of infected individuals do not show symptoms in the early stages of the disease, the effectiveness of these drugs has been limited. These drugs also cause side effects that lead to discontinuation of treatment in more than 30% of patients12. Moreover, these treatments require many doses over a prolonged duration, which results in poor patient adherence.

Drug Discovery Partnership


Committed to finding effective treatments for Chagas disease and VL, the GHIT Fund supported a drug discovery partnership between Drugs for Neglected Diseases Initiative (DNDi) and pharmaceutical companies Eisai Co. Ltd, Shionogi & Co. Ltd., and Takeda Pharmaceutical Companay Limited. This unique partnership provides DNDi with access to the drug discovery portfolios and scientific expertise of the companies for the purpose of finding new treatments for both diseases.

GHIT’s “Hit-to-Lead Platform (HTLP)” is at the heart of the partnership and is a drug discovery approach that allows for rapid screening of compounds to find those most promising for treatment. Testing is conducted in a step-wise manner; initially, thousands of diverse compounds are screened to find a few promising drug candidates called “hits.” Hits are then optimized to create “leads” suitable for human testing, of which the most safe and effective are eligible to become drugs.

The partnership improves the probability of finding new treatments as compared to drug discovery efforts conducted individually at each of participating entities and is expected to identify at least 4 hits each for Chagas disease and VL within the next 2 years. Hopes are high that these “hits” will provide at least one lead drug candidate for each disease, which can then be advanced through more detailed safety and effectiveness studies during development.

Although the partnership is in its early stage, the GHIT Fund and its development partners are already considering how Chagas disease and VL drugs can be made affordable and accessible. Some of these considerations include:
  • Testing – Extensive clinical testing must be performed to ensure that new Chagas disease and VL drugs are safer and more effective than currently available interventions. The development process itself must also be cost effective and efficient if these treatments are to become a reality. Since many of the compounds that will be evaluated by the HTLP are well characterized, the partnership has the potential to decrease the overall cost and time required for drug development.
  • Cost – Affordable treatment options will be essential for reducing the health and economic impacts of Chagas disease and VL, as endemic areas are often the most impoverished.
  • Stability – New treatment options must be stable enough to survive the temperature and humidity extremes of endemic areas. Otherwise, cost-effective shipping and storage requirements will need to be devised to ensure product integrity and patient access.
  • Administration – To best ensure patient adherence, treatments would ideally be administered orally and require minimal doses to be effective.